Abstract KRAS G12S mutations in non-small cell lung cancer (NSCLC) remain refractory to current targeted therapies, with few clinical options and frequent resistance. While CRISPR/Cas9 enables mutation-specific gene disruption, its pulmonary application is limited by systemic clearance, hepatic tropism, and...

Lung cancer remains the leading cause of cancer-related morbidity and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases [1]. KRAS mutation is one of the most common driver alterations in NSCLC, especially in...

Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyaluronidase alfa-pmph. The study targets the first-line treatment...

The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805), an investigational RAS(ON) KRAS G12D inhibitor, as a treatment for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring KRAS G12D mutations who have previously received anti–PD-(L)1...

The FDA has granted breakthrough therapy designation (BTD) to zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, in KRAS G12D-mutated, locally advanced or metastatic non–small cell lung cancer (NSCLC) previously treated with anti–PD-1/PD-L1 therapy and platinum-based chemotherapy.1 Zoldonrasib is a potent, orally...